0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]

Incyte Corporation (INCY)  More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte's oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free and first-line cancer care. Next, we'll examine how Minjuvi's expanded European and Japanese indications could reshape Incyte's investment narrative and future growth mix. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own Incyte, you generally need to believe that its expanding oncology portfolio can gradually rebalance dependence on Jakafi while funding further R&D. The Minjuvi and Zynyz approvals in Europe and Japan support that diversification effort, but do not change that the key near term catalyst remains execution on new product launches, and the biggest [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]

Incyte Corporation  (INCY) 
More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte's oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free and first-line cancer care. Next, we'll examine how Minjuvi's expanded European and Japanese indications could reshape Incyte's investment narrative and future growth mix. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own Incyte, you generally need to believe that its expanding oncology portfolio can gradually rebalance dependence on Jakafi while funding further R&D. The Minjuvi and Zynyz approvals in Europe and Japan support that diversification effort, but do not change that the key near term catalyst remains execution on new product launches, and the biggest [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS